1130115-44-4

Basic information

• Product Name: Sorafenib-d3
• Synonyms: Donafenib Tosylate
• CAS NO: 1130115-44-4
• Molecular Formula: C₂₁H₁₆ClF₃N₄O₃
• Molecular Weight: 464.8249496
• Product Categories: Inhibitors;Intermediates & Fine Chemicals;Isotope Labelled Compounds;Pharmaceuticals
• Mol File: 1130115-44-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 202-204?C
• Appearance: /
• Storage Temp.: -20°C Freezer
• CAS DataBase Reference: Sorafenib-d3(CAS DataBase Reference)
• NIST Chemistry Reference: Sorafenib-d3(1130115-44-4)
• EPA Substance Registry System: Sorafenib-d3(1130115-44-4)

Safety Data

• Hazardous Substances Data: 1130115-44-4(Hazardous Substances Data)

Usage

Chemical Properties

Off-White to Light Pink Solid

Uses

Labelled Sorafenib, a potent RAF kinase inhibitor. Antineoplastic.

Upstream product

• 1189858-48-7 4-chloropyridinyl-2-(N-1',1',1'-trideuteromethylcarboxamide) 
• 1187086-96-9 N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide 
• 1189975-18-5 4-(4-aminophenoxy)-2-pyridine-(N-(methyl-d₃))carboxamide 
• 59-67-6 nicotinic acid 
• 53750-66-6 4-chloro-pyridine-2-carbonyl chloride 
• 98-98-6 2-Picolinic acid 
• 327-78-6 4-chloro-3-(trifluoromethyl)phenyl isocyanate 
• 24484-93-3 4-Chloro-pyridine-2-carboxylic acid methyl ester 
• 5470-22-4 4-chloropicolinic acid 
• 1129683-83-5 4-[ ({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenol 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 
• 1012058-78-4 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinecarboxylic acid 
• 7436-22-8 methyl-d3-amine hydrochloride 
• 573673-43-5 methyl 4‐(4‐(3‐(4‐chloro‐3‐(trifluoromethyl)phenyl)ureido)phenoxy)picolinate 

Downstream Products

• 1333386-17-6 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxyl)-2-(N-1’,1’,1’-trideuteromethyl)pyridine amide p-toluenesulfonate 

Relevant articles and documents

Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities

Deuterium substitution has been widely known that can improve the pharmacokinetic profiles due to isotope effect. Herein, a series of deuterated sorafenib derivatives have been synthesized and characterized by 1H NMR, 13C NMR and MS. Their antitumor activities were evaluated in vitro against human hepatoma cell line HepG2 and human cervical carcinoma cell line HeLa. The LogP values were detected by high-performance liquid chromatography. Subsequently, the metabolic stability and pharmacokinetics study were assessed in vitro and in vivo.

Deuterated bisarylurea compound and preparation method thereof, and application of compound in preparation of antitumor drug

The invention provides a deuterated bisarylurea compound and a preparation method thereof, and application of the compound in preparation of an antitumor drug. The compound has a structure as shown in a general formula (I). The preparation method comprises the following steps: with methyl 4-chloropyridine-2-formate as a raw material, sucjecting methyl 4-chloropyridine-2-formate and methylamine or deuterated methylamine to a substitution reaction; then subjecting a product obtained in the previous step to condensation with p-aminophenol or deuterated p-aminophenol; and reacting a product obtained in the previous step with 4-chloro-3-(trifluoromethyl)phenyl isocyanate or deuterated 4-chloro-3-(trifluoromethyl)phenyl isocyanate so as to prepare the deuterated bisarylurea compound. Experiment results show that the deuterated bisarylurea compound provided by the invention has tumor treatment effect. The invention also provides application of the compound to research and development of the antitumor drug.

METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA

Methods and processes for preparation and production of deuterated ω-diphenylurea are disclosed. Especially, a kind of deuterated ω-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenye-N′-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.